NASDAQ$ARDX

Ardelyx Inc · Q2 2025 earnings

Q2 2025 earnings · · After market close · Investor relations

Briefing

Ardelyx reported increased product sales and total revenues for Q2 2025 compared to the prior year.

Ardelyx Inc. reported total revenues of $97.7 million for the three months ended June 30, 2025, driven primarily by product sales of IBSRELA and XPHOZAH. The company recorded a net loss of $19.1 million and continued investments in commercialization and R&D activities.

  • Product sales, net reached $90.1 million, with IBSRELA contributing $65.0 million and XPHOZAH $25.0 million.
  • Total revenues increased 33% year-over-year to $97.7 million, including product supply and royalty revenues.
  • Net loss widened to $19.1 million from $16.5 million in Q2 2024 due to higher operating expenses.
  • Cash and cash equivalents stood at $90.0 million with total assets of $466.8 million at quarter end.

Headline financials

Total Revenue

$97.7M

Previous: $73.2M+33.4%
EPS (adj)

-$0.08

Previous: -$0.07-14.3%
R&D Expenses

$15.7M

Previous: $12.8M+22.8%
SG&A Expenses

$84M

Previous: $64.7M+29.9%
Interest Expense

$4.36M

Previous: $3.33M+31.0%
Non-cash Interest on Royalties

$2.22M

Previous: $1.58M+40.8%
Other Income, Net

$1.89M

Previous: $2.15M-11.8%
Income Tax Provision

$1K

Previous: $67K-98.5%
Stock-based Compensation

$11.7M

No prior period
Capital Expenditures

-$975K

Previous: -$281K-247.0%
Net Income

-$19.1M

Previous: -$16.5M-16.0%
Operating Income

-$14.4M

Previous: -$13.6M-5.6%
Cash & Equivalents

$90M

Previous: $41.9M+115.0%
Total Assets

$467M

Previous: $343M+35.9%

Revenue & EPS history

Ardelyx · Revenue · Quarterly

$97.7M

Q2 2025+33.4%vs Q2 2024
Beat estimate in 13 of 16 quarters(81%)
ActualEstimate

Revenue by segment

Ardelyx · $90.1M total across 2 segments · Q2 2025

  • IBSRELA
    $65M
  • XPHOZAH
    $25M

Forward guidance

The company continues to focus on commercial growth of IBSRELA and XPHOZAH while advancing pipeline opportunities.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports

Historical avg

+0.0%

Avg return

Earnings day

+2.6%

Avg return

5 days after

+5.2%

Avg return

30 days after

40%

20 / 50 earnings

Positive

+31.9%

Q1 2024

Best reaction

-24.8%

Q1 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q2 2025
Q1 2026+6.2%+12.2%-4.7%
Q4 2025-14.9%-2.7%-21.2%
Q3 2025+18.6%+18.8%+15.8%
Q1 2025-24.8%-32.4%-32.9%
Q4 2024-10.1%-18.6%-19.3%
Q3 2024+3.4%-2.9%-3.7%
Q2 2024+9.0%+9.5%+11.4%
Q1 2024+31.9%+40.8%+3.8%
Q4 2023+2.1%+13.8%-9.4%
Q3 2023+8.8%+11.0%+24.6%
Q2 2023+4.2%-2.3%+25.5%
Q1 2023+5.9%-5.6%-20.7%
Q4 2022+30.8%+34.9%+64.0%
Q3 2022+0.7%-11.6%+25.9%
Q2 2022+11.5%+14.9%+42.5%
Q1 2022-10.7%-20.3%-26.0%
Q4 2021-7.6%+17.0%+37.1%
Q3 2021-3.4%-12.1%+25.9%
Q2 2021-1.3%-9.9%-10.5%
Q1 2021+0.6%+1.1%+0.5%
Q4 2020-4.8%+4.5%+14.2%
Q3 2020-6.3%+1.9%+10.3%
Q2 2020+1.4%-2.6%+0.7%
Q1 2020+2.2%+5.0%-4.2%
Q4 2019-7.3%-9.1%-12.6%
Q3 2019+2.2%+12.5%+22.1%
Q2 2019-3.8%-5.1%+108.1%
Q1 2019-4.7%-4.1%-22.3%
Q4 2018+8.0%+9.7%+9.0%
Q3 2018-6.7%-10.6%-29.4%
Q2 2018-7.1%+0.0%-7.1%
Q1 2018+0.0%+2.5%-24.8%
Q4 2017-5.0%-4.5%-6.2%
Q3 2017+2.2%+4.5%+8.2%
Q2 2017+11.0%+17.2%+29.9%
Q1 2017-2.2%-0.8%-63.4%
Q4 2016-2.4%-1.1%+13.7%
Q3 2016+2.5%+25.6%+21.3%
Q2 2016-0.8%-1.9%+5.8%
Q1 2016-0.5%
Q4 2015-5.6%
Q3 2015-4.4%
Q2 2015-2.8%
Q1 2015-0.4%
Q1 2014-0.4%
Q4 2014-5.2%
Q3 2013-5.5%
Q3 2014-5.5%
Q2 2013-1.3%
Q2 2014-5.2%
Q4 2013
Q1 2013

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro